22 results  1 of 2 

1 Cyclophosphamide, Bortezomib, and Dexamethasone Consolidation in Patients with Multiple Myeloma after Stem Cell Transplantation: The KMM130 Study
Jongheon Jung, Kihyun Kim, Sung-Hoon Jung, Sung-Soo Yoon, Jae Hoon Lee, Jin Seok Kim, Ho-Jin Shin, Soo-Mee Bang, Sang Kyun Sohn, Cheolwon Suh, Dok Hyun Yoon, Sun-Young Kong, Chang-Ki Min, Hyeon-Seok Eom
Cancer Res Treat.2023;55(2):693-703.   Published online 2022 November 16     DOI: http://dx.doi.org/10.4143/crt.2022.952
      
2 Outcomes of bortezomib combination chemotherapies in autologous stem cell transplantation-ineligible patients with AL amyloidosis
Joon Young Hur, Sang Eun Yoon, Darae Kim, Jin-oh Choi, Ju-Hong Min, Byung Jun Kim, Jung Sun Kim, Jung Eun Lee, Joon Young Choi, Eun-Seok Jeon, Seok Jin Kim, Kihyun Kim
Blood Res.2021;56(4):266-278.   Published online 2021 December 31     DOI: http://dx.doi.org/10.5045/br.2021.2021121
      
3 Acute antibody-mediated rejection limited to medullary lesions in following ABO-incompatible living donor kidney transplantation
A Young Kim, Kyu Hyang Cho, Jong Won Park, Jun Young Do, Man-Hoon Han, Yong-Jin Kim, Seok Hui Kang
Korean J Transplant.2021;35(1):53-58.   Published online 2021 March 5     DOI: http://dx.doi.org/10.4285/kjt.20.0047
      
4 Bortezomib Treatment for Refractory Antibody-Mediated Rejection Superimposed with BK Virus-Associated Nephropathy during the Progression of Recurrent C3 Glomerulonephritis
Wonseok Do, Jong-Hak Lee, Kyung Joo Kim, Man-Hoon Han, Hee-Yeon Jung, Ji-Young Choi, Sun-Hee Park, Yong-Lim Kim, Chan-Duck Kim, Jang-Hee Cho, Youngae Yang, Minjung Kim, Inryang Hwang, Kyu Yeun Kim, Taehoon Yim, Yong-Jin Kim
J Korean Soc Transplant.2018;32(3):57-62.   Published online 2018 September 27     DOI: http://dx.doi.org/10.4285/jkstn.2018.32.3.57
      
5 Chemotherapy adherence is a favorable prognostic factor for elderly patients with multiple myeloma who are treated with a frontline bortezomib-containing regimen
Hee-Jeong Cho, Sang-Kyung Seo, Dong Won Baek, Sung-Woo Park, Yoo-Jin Lee, Sang-Kyun Sohn, Ho-Sup Lee, Won Sik Lee, Ji Hyun Lee, Sung Hyun Kim, Joon-Ho Moon
Yeungnam Univ J Med.2018;35(1):76-83.   Published online 2018 June 30     DOI: http://dx.doi.org/10.12701/yujm.2018.35.1.76
      
6 The Effect of Bortezomib on the Management of Immediate Postoperative Refractory Antibody-Mediated Rejection after Kidney Transplantation
So-Jeong Kim, Kang-Woong Jun, Jeong-Kye Hwang, Byung-Ha Chung, Chul-Woo Yang, In-Sung Moon, Ji-il Kim, Mi-Hyeong Kim
J Korean Soc Transplant.2018;32(3):49-56.   Published online 2018 January 19     DOI: http://dx.doi.org/10.4285/jkstn.2018.32.3.49
   
7 Pralatrexate in Combination with Bortezomib for Relapsed or Refractory Peripheral T Cell Lymphoma in 5 Elderly Patients
Seung-Shin Lee, Sung-Hoon Jung, Jae-Sook Ahn, Yeo-Kyeoung Kim, Min-Seok Cho, Seung-Yeon Jung, Je-Jung Lee, Hyeoung-Joon Kim, Deok-Hwan Yang
J Korean Med Sci.2016;31(7):1160-1163.   Published online 2016 May 12     DOI: http://dx.doi.org/10.3346/jkms.2016.31.7.1160
      
8 Pretreatment Lymphopenia, Poor Performance Status, and Early Courses of Therapy Are Risk Factors for Severe Bacterial Infection in Patients with Multiple Myeloma during Treatment with Bortezomib-based Regimens
Shin Young Hyun, Sang Hoon Han, Soo-Jeong Kim, Ji Eun Jang, Yundeok Kim, Hyunsoo Cho, Jung Yeon Lee, June-Won Cheong, Yoo Hong Min, Jae-Woo Song, Jin Seok Kim
J Korean Med Sci.2016;31(4):510-518.   Published online 2016 February 22     DOI: http://dx.doi.org/10.3346/jkms.2016.31.4.510
      
9 The Effect of Bortezomib on Antibody-Mediated Rejection after Kidney Transplantation
Juhan Lee, Beom Seok Kim, Yongjung Park, Jae Geun Lee, Beom Jin Lim, Hyeon Joo Jeong, Yu Seun Kim, Kyu Ha Huh
Yonsei Med J.2015;56(6):1638-1642.   Published online 2015 September 25     DOI: http://dx.doi.org/10.3349/ymj.2015.56.6.1638
      
10 Bortezomib inhibits the survival and proliferation of bone marrow stromal cells
Ha-Yon Kim, Ji-Young Moon, Haewon Ryu, Yoon-Seok Choi, Ik-Chan Song, Hyo-Jin Lee, Hwan-Jung Yun, Samyong Kim, Deog-Yeon Jo
Blood Res.2015;50(2):87-96.   Published online 2015 June 25     DOI: http://dx.doi.org/10.5045/br.2015.50.2.87
      
11 The Effect of Bortezomib on Expression of Inflammatory Cytokines and Survival in a Murine Sepsis Model Induced by Cecal Ligation and Puncture
Sang Hoon Han, Jin Seok Kim, Jun Hee Woo, Su Jin Jeong, Jeon-Soo Shin, Young Soo Ahn, June Myung Kim
Yonsei Med J.2015;56(1):112-123.   Published online 2014 December 10     DOI: http://dx.doi.org/10.3349/ymj.2015.56.1.112
      
12 Use of Bortezomib as Anti-Humoral Therapy in Kidney Transplantation
Keun Suk Yang, Howook Jeon, Youngjae Park, Ik Hyun Jo, Ji-Il Kim, In Sung Moon, Bum Soon Choi, Cheol Whee Park, Chul Woo Yang, Yong-Soo Kim, Byung Ha Chung
J Korean Med Sci.2014;29(5):648-651.   Published online 2014 April 25     DOI: http://dx.doi.org/10.3346/jkms.2014.29.5.648
      
13 Poor prognostic significance of Mycobacterium tuberculosis infection during bortezomib-containing chemotherapy in patients with multiple myeloma
Jae-Sook Ahn, Sung Yoon Rew, Deok-Hwan Yang, Sung-Hoon Jung, Seung-Ji Kang, Mi-Young Kim, Seung-Shin Lee, Yeo-Kyeoung Kim, Hyeoung-Joon Kim, Je-Jung Lee
Blood Res.2013;48(1):35-39.   Published online 2013 March 25     DOI: http://dx.doi.org/10.5045/br.2013.48.1.35
      
14 Early Response to Bortezomib Combined Chemotherapy Can Help Predict Survival in Patients with Multiple Myeloma Who Are Ineligible for Stem Cell Transplantation
Ho Sup Lee, Yang Soo Kim, Kihyun Kim, Jin Seok Kim, Hyo Jung Kim, Chang-Ki Min, Cheolwon Suh, Hyeon-Seok Eom, Sung-Soo Yoon, Jae Hoon Lee, Min Kyong Kim, Sung-Hyun Kim, Sung Hwa Bae, Yeung-Chul Mun, Deog Yeon Jo, Joo-Seop Chung,
J Korean Med Sci.2013;28(1):80-86.   Published online 2013 January 8     DOI: http://dx.doi.org/10.3346/jkms.2013.28.1.80
      
15 A Case of Drug-Induced Hepatitis due to Bortezomib in Multiple Myeloma
Youngwoon Kim, Ka Young Kim, Su Hyun Lee, Yoon Yung Chung, Seung-Ah Yahng, Sung-Eun Lee, Gyeongsin Park, Chang-Ki Min
Immune Netw.2012;12(3):126-128.   Published online 2012 June 30     DOI: http://dx.doi.org/10.4110/in.2012.12.3.126
      
16 A phase I/II study of bortezomib plus CHOP every 2 weeks (CHOP-14) in patients with advanced-stage diffuse large B-cell lymphomas
Jeong Eun Kim, Dok Hyun Yoon, Geundoo Jang, Dae Ho Lee, Shin Kim, Chan-Sik Park, Jooryung Huh, Won Seog Kim, Jinny Park, Jae Hoon Lee, Soon Il Lee, Cheolwon Suh
Korean J Hematol.2012;47(1):53-59.   Published online 2012 March 28     DOI: http://dx.doi.org/10.5045/kjh.2012.47.1.53
      
17 Complete Atrioventricular Block Secondary to Bortezomib Use in Multiple Myeloma
Won-Seop Lee, Dae-Hyeok Kim, Sung-Hee Shin, Seoung-Il Woo, Jun Kwan, Keum-Soo Park, Sang-Don Park, Hyeon-Gyu Yi, Sang-Hoon Jeon
Yonsei Med J.2011;52(1):196-198.   Published online 2010 November 30     DOI: http://dx.doi.org/10.3349/ymj.2011.52.1.196
      
18 Bortezomib and melphalan as a conditioning regimen for autologous stem cell transplantation in multiple myeloma
Se Ryeon Lee, Seok Jin Kim, Yong Park, Hwa Jung Sung, Chul Won Choi, Byung Soo Kim
Korean J Hematol.2010;45(3):183-187.   Published online 2010 September 30     DOI: http://dx.doi.org/10.5045/kjh.2010.45.3.183
      
19 Nonspecific Interstitial Pneumonitis after Bortezomib and Thalidomide Treatment in a Multiple Myeloma Patient
Wonseok Kang, Jin Seok Kim, Sang Ho Cho, Sung Kyu Kim, Joon Chang, Moo Suk Park
Yonsei Med J.2010;51(3):448-450.   Published online 2010 April 1     DOI: http://dx.doi.org/10.3349/ymj.2010.51.3.448
      
20 Combination Therapy of Bortezomib (PS-341) and SAHA (Vorinostat) in Non-Small Cell Lung Cancer Cell Lines
Mi-Young Park, Dal Rae Kim, Jong-Sun Park, Young-Jae Cho, Sei-Won Lee, Ho-Il Yoon, Jae Ho Lee, Choon-Taek Lee
J Lung Cancer.2010;9(2):77-84.   Published online 2010 January 10     DOI: http://dx.doi.org/10.6058/jlc.2010.9.2.77
   

 1 of 2